Gene Therapy on Cardiovascular Disease Market
完整報告名稱與涵蓋範圍
Gene Therapy on Cardiovascular Disease Market Size, Share & Trends Analysis Report By Type (Viral Gene Therapy, Non-Viral Gene Therapy), By Application (Heart Disease, Vascular Disease), By Region, And By Segment Forecasts, 2024-2031.
報告摘要
The Gene Therapy on Cardiovascular Disease Market is positioned for steady expansion, with a projected CAGR of 67.4% from 2024 to 2031.
Gene Therapy on Cardiovascular Disease covers reshaping how healthcare entities approach this space.
Market momentum is supported by rising interest in advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy on Cardiovascular Disease Market Snapshot
Chapter 4. Global Gene Therapy on Cardiovascular Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Viral Gene Therapy
5.2.2. Non-Viral Gene Therapy
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Heart Disease
6.2.2. Vascular Disease
Chapter 7. Gene Therapy on Cardiovascular Disease Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.1.2. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.1.3. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.2.2. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.2.3. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.3.2. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.3.3. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.4.2. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.4.3. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.5.2. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.5.3. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Biogen
8.2.2. Novartis
8.2.3. Gilead Sciences
8.2.4. Sarepta Therapeutics
8.2.5. Alnylam Pharmaceuticals
8.2.6. Amgen
8.2.7. Spark Therapeutics
8.2.8. Akcea Therapeutics
8.2.9. Sunway Biotech
8.2.10. bluebird bio
8.2.11. SIBIONO
8.2.12. AnGes
8.2.13. Orchard Therapeutics
8.2.14. Other Market Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們